Literature DB >> 25135378

Analysis of patients with atypical hemolytic uremic syndrome treated at the Mie University Hospital: concentration of C3 p.I1157T mutation.

Takeshi Matsumoto1, Xinping Fan, Eiji Ishikawa, Masaaki Ito, Keishirou Amano, Hidemi Toyoda, Yoshihiro Komada, Kohshi Ohishi, Naoyuki Katayama, Yoko Yoshida, Masanori Matsumoto, Yoshihiro Fujimura, Makoto Ikejiri, Hideo Wada, Toshiyuki Miyata.   

Abstract

Atypical hemolytic uremic syndrome (aHUS) is caused by abnormalities of the complement system and has a significantly poor prognosis. The clinical phenotypes of 12 patients in nine families with aHUS with familial or recurrent onset and ADAMTS13 activity of ≥20 % treated at the Mie University Hospital were examined. In seven of the patients, the first episode of aHUS occurred during childhood and ten patients experienced a relapse. All patients had renal dysfunction and three had been treated with hemodialysis. Seven patients experienced probable triggering events including common cold, influenza, bacterial infection and/or vaccination for influenza. All patients had entered remission, and renal function was improved in 11 patients. DNA sequencing of six candidate genes, identified a C3 p.I1157T missense mutation in all eight patients in six families examined and this mutation was causative for aHUS. A causative mutation THBD p.D486Y was also identified in an aHUS patient. Four missense mutations, CFH p.V837I, p.Y1058H, p.V1060L and THBD p.R403K may predispose to aHUS manifestation; the remaining seven missense mutations were likely neutral. In conclusion, the clinical phenotypes of aHUS are various, and there are often trigger factors. The C3 p.I1157T mutation was identified as the causative mutation for aHUS in all patients examined, and may be geographically concentrated in or around the Mie prefecture in central Japan.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25135378     DOI: 10.1007/s12185-014-1655-2

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  25 in total

Review 1.  Membranoproliferative glomerulonephritis--a new look at an old entity.

Authors:  Sanjeev Sethi; Fernando C Fervenza
Journal:  N Engl J Med       Date:  2012-03-22       Impact factor: 91.245

2.  Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.

Authors:  Lothar Bernd Zimmerhackl; Johannes Hofer; Gérard Cortina; Walter Mark; Reinhard Würzner; Therese C Jungraithmayr; Gus Khursigara; Kay O Kliche; Wolfgang Radauer
Journal:  N Engl J Med       Date:  2010-05-06       Impact factor: 91.245

Review 3.  Alternative complement pathway assessment in patients with atypical HUS.

Authors:  Lubka T Roumenina; Chantal Loirat; Marie-Agnes Dragon-Durey; Lise Halbwachs-Mecarelli; Catherine Sautes-Fridman; Veronique Fremeaux-Bacchi
Journal:  J Immunol Methods       Date:  2011-01-06       Impact factor: 2.303

Review 4.  Atypical hemolytic-uremic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

5.  A second national questionnaire survey of TMA.

Authors:  Naomi Ito-Habe; Hideo Wada; Masanori Matsumoto; Yoshihiro Fujimura; Mitsuru Murata; Takashi Izuno; Minoru Sugita; Yasuo Ikeda
Journal:  Int J Hematol       Date:  2010-06-05       Impact factor: 2.490

6.  Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.

Authors:  Marina Noris; Jessica Caprioli; Elena Bresin; Chiara Mossali; Gaia Pianetti; Sara Gamba; Erica Daina; Chiara Fenili; Federica Castelletti; Annalisa Sorosina; Rossella Piras; Roberta Donadelli; Ramona Maranta; Irene van der Meer; Edward M Conway; Peter F Zipfel; Timothy H Goodship; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 8.237

Review 7.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.

Authors:  Phillip I Tarr; Carrie A Gordon; Wayne L Chandler
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

8.  Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H.

Authors:  P Sánchez-Corral; C González-Rubio; S Rodríguez de Córdoba; M López-Trascasa
Journal:  Mol Immunol       Date:  2004-05       Impact factor: 4.407

9.  Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.

Authors:  Anne-Laure Sellier-Leclerc; Veronique Fremeaux-Bacchi; Marie-Agnès Dragon-Durey; Marie-Alice Macher; Patrick Niaudet; Geneviève Guest; Bernard Boudailliez; François Bouissou; Georges Deschenes; Sophie Gie; Michel Tsimaratos; Michel Fischbach; Denis Morin; Hubert Nivet; Corinne Alberti; Chantal Loirat
Journal:  J Am Soc Nephrol       Date:  2007-06-28       Impact factor: 10.121

10.  Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Authors:  C M Legendre; C Licht; P Muus; L A Greenbaum; S Babu; C Bedrosian; C Bingham; D J Cohen; Y Delmas; K Douglas; F Eitner; T Feldkamp; D Fouque; R R Furman; O Gaber; M Herthelius; M Hourmant; D Karpman; Y Lebranchu; C Mariat; J Menne; B Moulin; J Nürnberger; M Ogawa; G Remuzzi; T Richard; R Sberro-Soussan; B Severino; N S Sheerin; A Trivelli; L B Zimmerhackl; T Goodship; C Loirat
Journal:  N Engl J Med       Date:  2013-06-06       Impact factor: 91.245

View more
  21 in total

1.  aHUS associated with C3 gene mutation: a case with numerous relapses and favorable 20-year outcome.

Authors:  Ekaterini Siomou; Athanasios Gkoutsias; Anastasios Serbis; Konstantinos Kollios; Nikolaos Chaliasos; Veronique Frémeaux-Bacchi
Journal:  Pediatr Nephrol       Date:  2015-11-16       Impact factor: 3.714

2.  Occurrence of atypical HUS associated with influenza B.

Authors:  Karen van Hoeve; Corinne Vandermeulen; Marc Van Ranst; Elena Levtchenko; Lambert van den Heuvel; Djalila Mekahli
Journal:  Eur J Pediatr       Date:  2017-01-21       Impact factor: 3.183

3.  Atypical haemolytic uremic syndrome from multiple missenses to a full-blown disease.

Authors:  Filipe Santos Mira; Ana Luísa Nunes; Ana Rita Elvas; Nuno Oliveira
Journal:  BMJ Case Rep       Date:  2019-06-27

4.  Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome.

Authors:  Elizabeth C Schramm; Lubka T Roumenina; Tania Rybkine; Sophie Chauvet; Paula Vieira-Martins; Christophe Hue; Tara Maga; Elisabetta Valoti; Valerie Wilson; Sakari Jokiranta; Richard J H Smith; Marina Noris; Tim Goodship; John P Atkinson; Veronique Fremeaux-Bacchi
Journal:  Blood       Date:  2015-01-21       Impact factor: 22.113

5.  No association between dysplasminogenemia with p.Ala620Thr mutation and atypical hemolytic uremic syndrome.

Authors:  Toshiyuki Miyata; Yumiko Uchida; Yoko Yoshida; Hideki Kato; Masanori Matsumoto; Koichi Kokame; Yoshihiro Fujimura; Masaomi Nangaku
Journal:  Int J Hematol       Date:  2016-05-18       Impact factor: 2.490

6.  Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency.

Authors:  Xinping Fan; Johanna A Kremer Hovinga; Hiroko Shirotani-Ikejima; Yuka Eura; Hidenori Hirai; Shigenori Honda; Koichi Kokame; Magnus Mansouri Taleghani; Anne-Sophie von Krogh; Yoko Yoshida; Yoshihiro Fujimura; Bernhard Lämmle; Toshiyuki Miyata
Journal:  Int J Hematol       Date:  2016-02-01       Impact factor: 2.490

7.  Chikungunya virus as a trigger for different renal disorders: an exploratory study.

Authors:  Denise Maria do Nascimento Costa; Carlos Eduardo Machado; Precil Diego Neves; Dyego José Brito; Samira Oi; Flávio Henrique Barros; Luiz Tadeu Figueiredo; Stanley Almeida Araujo; Francisco Ladchumananandasivam; Marlene Antônia Dos Reis; Weverton Luchi; Joyce Lages; Natalino Salgado Filho; Luiz Fernando Onuchic; Angela Luzia Duarte; Claudia Diniz Lopes Marques; Maria Rosângela Cunha Duarte Coêlho; Camila Oliveira; Gisele Vajgel; Maria Alina Cavalcante; Lucila Valente; Vera Magalhães; Gyl Eanes Barros Silva
Journal:  J Nephrol       Date:  2022-02-04       Impact factor: 4.393

8.  The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome.

Authors:  Rubén Martínez-Barricarte; Meike Heurich; Andrés López-Perrote; Agustin Tortajada; Sheila Pinto; Margarita López-Trascasa; Pilar Sánchez-Corral; B Paul Morgan; Oscar Llorca; Claire L Harris; Santiago Rodríguez de Córdoba
Journal:  Mol Immunol       Date:  2015-04-11       Impact factor: 4.407

9.  New functional and structural insights from updated mutational databases for complement factor H, Factor I, membrane cofactor protein and C3.

Authors:  Elizabeth Rodriguez; Pavithra M Rallapalli; Amy J Osborne; Stephen J Perkins
Journal:  Biosci Rep       Date:  2014-10-22       Impact factor: 3.840

10.  Postoperative atypical hemolytic uremic syndrome associated with complement c3 mutation.

Authors:  Eiji Matsukuma; Atsushi Imamura; Yusuke Iwata; Takamasa Takeuchi; Yoko Yoshida; Yoshihiro Fujimura; Xinping Fan; Toshiyuki Miyata; Takashi Kuwahara
Journal:  Case Rep Nephrol       Date:  2014-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.